{
    "clinical_study": {
        "@rank": "28377", 
        "arm_group": [
            {
                "arm_group_label": "Rotigotine in Japanese subjects", 
                "arm_group_type": "Experimental", 
                "description": "Repeated-Dose application of 1,2, and 4 mg / 24 hours Rotigotine in healthy Japanese subjects; Transdermal patch over 24 hours"
            }, 
            {
                "arm_group_label": "Rotigotine in Caucasian subjects", 
                "arm_group_type": "Experimental", 
                "description": "Multiple-Dose application of 1, 2, and 4 mg / 24 hours Rotigotine in healthy Caucasian subjects; Transdermal patch over 24 hours"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the repeated dose Pharmacokinetics (PK) of transdermally delivered Rotigotine\n      in Japanese and Caucasian female and male healthy subjects."
        }, 
        "brief_title": "Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is healthy according to assessments done at eligibility assessment (medical\n             history, physical examination, blood pressure, heart rate, ECG, hematology, clinical\n             chemistry, urinalysis)\n\n          -  Subject is of normal body-weight as determined by a body mass index ranging between\n             18 to 28 kg/m\u00b2\n\n          -  Subject is Japanese or Caucasian. Japanese subjects are born in Japan and left Japan\n             not more than 10 years ago. Both parents of the Japanese subjects are 100 % Japanese\n\n        Exclusion Criteria:\n\n          -  Subjects (females) without medically adequate contraception  or on lactation or\n             pregnant women. Subjects with oral contraception or hormone replacement within 4\n             weeks prior to eligibility assessment\n\n          -  Subject has a history of chronic alcohol or drug abuse\n\n          -  Subject has a consumption of more than 20 g of alcohol/day (amount corresponds to 0.5\n             l of beer/day or 0.25 l of wine/day or 3 glasses (\u00e0 2 cl) of liquor/day)\n\n          -  Subject has a clinically relevant allergy\n\n          -  Subject has a known or suspected drug hypersensitivity in particular, to any\n             component of the trial medication\n\n          -  Subject has any clinically significant abnormality in physical examination\n\n          -  Subject has a heart rate at rest less than 50 beats per minute (bpm) or more than 100\n             bpm\n\n          -  Subject has systolic blood pressure lower than 100 mmHg or higher than 145 mmHg or\n             diastolic blood pressure higher than 95 mmHg or lower than 60 mmHg\n\n          -  Subject has an atopic or eczematous dermatitis and/or an active skin disease or skin\n             tumors\n\n          -  Subject has a history of significant skin hypersensitivity to adhesives or other\n             transdermal products or recent unresolved contact dermatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "26", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01854216", 
            "org_study_id": "SP718"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rotigotine in Japanese subjects", 
                    "Rotigotine in Caucasian subjects"
                ], 
                "description": "Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours", 
                "intervention_name": "Rotigotine transdermal patch 1mg / 24 hours", 
                "intervention_type": "Drug", 
                "other_name": "Neupro"
            }, 
            {
                "arm_group_label": [
                    "Rotigotine in Japanese subjects", 
                    "Rotigotine in Caucasian subjects"
                ], 
                "description": "Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours", 
                "intervention_name": "Rotigotine transdermal patch 2 mg / 24 hours", 
                "intervention_type": "Drug", 
                "other_name": "Neupro"
            }, 
            {
                "arm_group_label": [
                    "Rotigotine in Japanese subjects", 
                    "Rotigotine in Caucasian subjects"
                ], 
                "description": "Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours", 
                "intervention_name": "Rotigotine transdermal patch 4 mg / 24 hours", 
                "intervention_type": "Drug", 
                "other_name": "Neupro"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "N 0437"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Rotigotine", 
            "Neupro", 
            "Japanese", 
            "Caucasian", 
            "Male", 
            "Female", 
            "Single dose", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "May 10, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany"
                }, 
                "name": "1"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Parallel Group Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Repeated Dose Treatment With Rotigotine Continuous Delivery System (5 cm^2/2.25 mg, 10 cm^2/4.5 mg, 20 cm^2/9 mg) in Japanese and Caucasian Healthy Subjects", 
        "overall_official": {
            "affiliation": "+1 877 822 9493 (UCB)", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Area under the concentration-time curve of unconjugated Rotigotine in steady-state within one dosing interval  (AUCtau,ss)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Area under the concentration-time curve of unconjugated Rotigotine in steady-state within one dosing interval  normalized by Body Weight [AUCtau,ss,norm(BW)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of unconjugated Rotigotine in plasma at steady-state (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of unconjugated Rotigotine in plasma at steady-state normalized by Body Weight [Cmax,ss,norm(BW)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of unconjugated Rotigotine in plasma at steady-state normalized by apparent dose [Cmax,ss,norm(appd)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of unconjugated Rotigotine in plasma at steady-state normalized by Body Weight and apparent dose [Cmax,ss,norm(BW,appd)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Area under the concentration-time curve of total Rotigotine in steady-state within one dosing interval  (AUCtau,ss)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Area under the concentration-time curve of total Rotigotine in steady-state within one dosing interval  normalized by Body Weight [AUCtau,ss,norm(BW)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of total Rotigotine in plasma at steady-state (Cmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of total Rotigotine in plasma at steady-state normalized by Body Weight [Cmax,ss,norm(BW)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of total Rotigotine in plasma at steady-state normalized by apparent dose [Cmax,ss,norm(appd)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Maximum concentration of total Rotigotine in plasma at steady-state normalized by Body Weight and apparent dose [Cmax,ss,norm(BW,appd)]", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01854216"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Terminal half-life (t1/2) of unconjugated Rotigotine in steady-state", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours"
            }, 
            {
                "measure": "Time of maximum concentration (tmax) of unconjugated Rotigotine in steady-state (tmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Apparent total body clearance of unconjugated Rotigotine normalized by Body Weight (CL/f/BW)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Apparent volume of distribution of unconjugated Rotigotine normalized by Body Weight (Vz/f/BW)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours"
            }, 
            {
                "measure": "Terminal half-life (t1/2) of total Rotigotine in steady-state", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours"
            }, 
            {
                "measure": "Time of maximum concentration (tmax) of total Rotigotine in steady-state (tmax,ss)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Apparent total body clearance of total Rotigotine normalized by Body Weight (CL/f/BW)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, and 24 hours"
            }, 
            {
                "measure": "Apparent volume of distribution of total Rotigotine normalized by Body Weight (Vz/f/BW)", 
                "safety_issue": "No", 
                "time_frame": "Blood sampling at 0 hours (predose), 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, 16 hours, 24 hours, 25 hours, 26 hours, 28 hours, 30 hours, 33 hours, 36 hours, 48 hours"
            }
        ], 
        "source": "UCB, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UCB BIOSCIENCES GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2002", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}